Please use this identifier to cite or link to this item:
|Title:||Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand|
|Keywords:||Immunology and Microbiology;Medicine|
|Citation:||Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.89, No.6 (1995), 668-671|
|Abstract:||One hundred and two Thai patients with severe falciparum malaria (92 males and 10 females) were allocated at random to receive either the standard regimen of quinine infusion (52 cases) or intramuscular artemether (50 cases). The patients in both groups had comparable admission clinical and laboratory data. Artemether gave a better survival rate (87.2% vs. 63.3%) and parasite clearance time (54 vs. 78 h) than quinine. Fever clearance times (79 h vs. 84 h) and time to recovery of consciousness (48 h in both groups) were comparable. Previous treatment with quinine or mefloquine had no influence on treatment outcome. The most common adverse effect in patients treated with quinine was tinnitus. Two patients had severe hearing impairment which resolved within 1 week after the end of treatment. Mild, transient pain was noted at the injection site of artemether but no abscess formed QTc wave prolongation was seen in most patients receiving quinine; however, no arrhythmia was observed despite the high concentration of quininein some patients who had received quinine beforeadmission. Complications developed in 7 survivors in each treatment group. No patient in the artemether group had neurological sequelae after recovery of consciousness, but 2 in the quinine group had left facial palsy and one had a myasthenia gravis-like syndrome. No patient died with complications in the artemether group, but 7 died with pulmonary complications in the quinine group. © 1995 Oxford University Press.|
|Appears in Collections:||Scopus 1991-2000|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.